Sean Werner - BioLife Solutions Chief Officer
| BLFS Stock | USD 25.06 0.42 1.65% |
Executive
Sean Werner is Chief Officer of BioLife Solutions
| Address | 3303 Monte Villa Parkway, Bothell, WA, United States, 98021 |
| Phone | 425 402 1400 |
| Web | https://www.biolifesolutions.com |
Sean Werner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sean Werner against BioLife Solutions stock is an integral part of due diligence when investing in BioLife Solutions. Sean Werner insider activity provides valuable insight into whether BioLife Solutions is net buyers or sellers over its current business cycle. Note, BioLife Solutions insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioLife Solutions'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sean Werner over three months ago Insider Trading |
BioLife Solutions Management Efficiency
The company has return on total asset (ROA) of (0.011) % which means that it has lost $0.011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0332) %, meaning that it created substantial loss on money invested by shareholders. BioLife Solutions' management efficiency ratios could be used to measure how well BioLife Solutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.12 in 2025. Return On Capital Employed is likely to drop to -0.02 in 2025. At this time, BioLife Solutions' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 263.3 M in 2025, whereas Return On Tangible Assets are likely to drop (0.12) in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Hemanth Reddy | ResMed Inc | N/A | |
| Niro Ramachandran | Akoya Biosciences | 50 | |
| Dr CFA | West Pharmaceutical Services | 57 | |
| Jim Ellis | ResMed Inc | N/A | |
| Howard Cyr | Teleflex Incorporated | N/A | |
| Daniel Ackerman | AptarGroup | 52 | |
| Daniel Cravens | Alcon AG | N/A | |
| Rudy Poussot | West Pharmaceutical Services | N/A | |
| Dawn Haake | ResMed Inc | N/A | |
| Kenneth Miller | Repro Med Systems | 56 | |
| Jennifer Kamocsay | Akoya Biosciences | 54 | |
| Laurie Miller | Haemonetics | 51 | |
| Scott Centea | AngioDynamics | 45 | |
| Mary Skafidas | AptarGroup | N/A | |
| Jan MD | Haemonetics | N/A | |
| Kathy DePadua | West Pharmaceutical Services | N/A | |
| Douglas Seith | AtriCure | 59 | |
| Christopher Pazdan | Repro Med Systems | 42 | |
| Priyam Shah | Akoya Biosciences | N/A | |
| Anthony Catalano | Akoya Biosciences | N/A | |
| Michele Polinsky | West Pharmaceutical Services | N/A | |
Management Performance
| Return On Equity | -0.0332 | ||||
| Return On Asset | -0.011 |
BioLife Solutions Leadership Team
Elected by the shareholders, the BioLife Solutions' board of directors comprises two types of representatives: BioLife Solutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLife. The board's role is to monitor BioLife Solutions' management team and ensure that shareholders' interests are well served. BioLife Solutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLife Solutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Aby Mathew, Chairman of Scientific Advisory Board, CTO and Sr. VP | ||
| Sarah JD, Chief Officer | ||
| Troy Wichterman, Chief Officer | ||
| Geraint Phillips, Senior Operations | ||
| Todd Berard, Vice President of Marketing | ||
| Karen Foster, Vice President - Operations | ||
| Troy CPA, Chief Officer | ||
| Sean Werner, Chief Officer | ||
| Marcus Schulz, Chief Officer | ||
| Michael Rice, CEO and President and Director | ||
| Roderick Greef, Interim CFO, Interim Secretary |
BioLife Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioLife Solutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0332 | ||||
| Return On Asset | -0.011 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 1.12 B | ||||
| Shares Outstanding | 46.91 M | ||||
| Shares Owned By Insiders | 1.84 % | ||||
| Shares Owned By Institutions | 98.16 % | ||||
| Number Of Shares Shorted | 3.37 M | ||||
| Price To Earning | 173.59 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for BioLife Stock Analysis
When running BioLife Solutions' price analysis, check to measure BioLife Solutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLife Solutions is operating at the current time. Most of BioLife Solutions' value examination focuses on studying past and present price action to predict the probability of BioLife Solutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLife Solutions' price. Additionally, you may evaluate how the addition of BioLife Solutions to your portfolios can decrease your overall portfolio volatility.